Hørsholm, August 20, 2026 – MC2 Therapeutics, a commercial‑stage pharmaceutical company focused on topical therapies in inflammatory skin conditions, announces that its Canadian partner Knight Therapeutics Inc. (TSX: GUD) has launched Wynzora® Cream for the topical treatment of psoriasis vulgaris in adults and adolescents aged 12 and older in Canada.
Wynzora® is a once‑daily, PAD Technology™‑enabled aqueous cream that unites calcipotriol and betamethasone dipropionate in a clinically proven, convenient‑to‑use formulation. For many Canadians living with plaque psoriasis, control is limited not only by efficacy but also by tolerability and ease of use; Wynzora® is designed to help address this gap by combining strong scientific evidence with a patient‑acceptable cream format.
The launch builds on Health Canada’s approval in 2025 and forms part of MC2’s mission to make PAD Technology™‑enabled treatments available to more people living with psoriasis globally, in close collaboration with leading partners such as Knight Therapeutics.
For more information, please see the press-release: Knight Therapeutics Announces Launch of WYNZORA® in Canada or visit Knight Therapeutics at www.knighttx.com.
BACK
